Breast and prostate cancers are leading causes of cancer-related deaths throughout the world. In most cases, both diseases depend on sex hormones to promote their pathogenesis. Consequently, hormone-based therapies are used to prevent or delay disease progression. While these therapies often show initial improvements in disease-free survival, resistance invariably arises in most patients. Understanding and overcoming the mechanisms of hormone therapy resistance remains a critical field of study.
In this special issue, we welcome papers focusing on mechanisms of how breast, prostate, and other hormone-dependent cancers become resistant to their hormone therapies. We welcome original research articles, reviews, mini-reviews, and opinions/perspectives focused on novel diagnostic and therapeutic approaches to identify and overcome hormone therapy resistance in cancer.
Breast and prostate cancers are leading causes of cancer-related deaths throughout the world. In most cases, both diseases depend on sex hormones to promote their pathogenesis. Consequently, hormone-based therapies are used to prevent or delay disease progression. While these therapies often show initial improvements in disease-free survival, resistance invariably arises in most patients. Understanding and overcoming the mechanisms of hormone therapy resistance remains a critical field of study.
In this special issue, we welcome papers focusing on mechanisms of how breast, prostate, and other hormone-dependent cancers become resistant to their hormone therapies. We welcome original research articles, reviews, mini-reviews, and opinions/perspectives focused on novel diagnostic and therapeutic approaches to identify and overcome hormone therapy resistance in cancer.